Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.60 |
| ▸ | KCNQ3 | O43525 | 18/20 | 0.55 |
| ▸ | KCNQ2 | O43526 | 18/20 | 0.55 |
| ▸ | KCNE1 | P15382 | 12/20 | 0.52 |
| ▸ | KCNQ1 | P51787 | 12/20 | 0.52 |
| ▸ | BACE1 | P56817 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21623183 | 0.82 | KCNQ3 (0.61) | KCNQ3KCNQ2KCNE1KCNQ1BACE1 | |
| SCHEMBL21623542 | 0.80 | CYP1A2 (0.69) | CYP1A2RAB9ASMN1; SMN2 | |
| SCHEMBL21623572 | 0.78 | CYP1A2 (0.74) | CYP1A2SMN1; SMN2 | |
| SCHEMBL21623539 | 0.75 | CYP1A2 (0.84) | CYP1A2 | |
| SCHEMBL21623334 | 0.75 | CYP1A2 (1.00) | CYP1A2 | |
| SCHEMBL21623573 | 0.74 | CYP1A2 (0.68) | CYP1A2SMN1; SMN2 | |
| SCHEMBL21623564 | 0.73 | CYP1A2 (0.67) | CYP1A2KCNQ3KCNQ2KCNE1KCNQ1 | |
| SCHEMBL21623540 | 0.73 | CYP1A2 (0.65) | CYP1A2 | |
| SCHEMBL6106141 | 0.72 | KCNQ3 (0.64) | KCNQ3KCNQ2KCNE1KCNQ1BACE1 | |
| SCHEMBL14363248 | 0.72 | RAB9A (0.57) | KCNQ3KCNQ2KCNE1KCNQ1BACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210276967-A1 | INHIBITORS OF HEPATITIS B VIRUS | OSPEDALE SAN RAFFAELE S.R.L. (IT) | 2021-09-09 | — | — | US | disclosed |
| US-20210276967-A1 | INHIBITORS OF HEPATITIS B VIRUS | OSPEDALE SAN RAFFAELE S.R.L. (IT) | 2021-09-09 | — | — | US | disclosed |
| EP-3597637-A1 | INHIBITORS OF HEPATITIS B VIRUS | IRBM S.P.A. (IT) | 2020-01-22 | — | — | EP | disclosed |
| EP-3597637-A1 | INHIBITORS OF HEPATITIS B VIRUS | IRBM S.P.A. (IT) | 2020-01-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210276967-A1 | INHIBITORS OF HEPATITIS B VIRUS | HAVCR2, SLC10A1, HDGF | CYP1A2 1300/4885KCNQ3 4616/4885KCNQ2 4490/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.